KULA, Maui, April 16 /PRNewswire/ -- Bioponic Phytoceuticals, Inc. (OTC: BPYT - News; "Bioponic" or "the Company") today announced that curcumin, the key ingredient in the Company's Curecumin(TM) product (a Bioresonant Phytotherapeutic® form of curcumin in a liquid delivery system) may be an important treatment for lowering heart failure risk. Bioponic currently sells Curecumin in a 1 oz. oral spray and a 1 oz. nasal pump spray bottle. Research findings and product information on Curecumin's many therapeutic qualities can be found at http://www.curecumin.com.
In a recent study entitled, "Curcumin prevents and reverses murine cardiac hypertrophy," published in the February 2008 edition of the Journal of Clinical Investigation, researchers found that when the herb was given orally to a variety of mouse models with enlarged hearts (hypertrophy), it can prevent and reverse hypertrophy, restore heart function and reduce scar formation.
"Whether you are young or old; male or female; the larger your heart is, the higher your risk is for developing heart attacks or heart failure in the future," explains Dr. Liu, a cardiologist in the Peter Munk Cardiac Centre at the Canadian Institutes of Health Research - Institute of Circulatory and Respiratory Health. If clinical trials of curcumin support initial findings of heart enlargement prevention, it may offer hope for millions of patients with heart enlargement. Dr. Liu, who holds the Heart and Stroke Foundation's Polo Chair Professor in Medicine and Physiology at the University of Toronto, says that curcumin may be a safe and effective means of preventing heart failure in the future. This study was funded by the Heart and Stroke Foundation and the Canadian Institutes of Health Research.
"Curcumin has been the subject of extensive research over the past few years, and has been shown to protect the liver, inhibit tumors, reduce inflammation and prevent the formation of the amyloid beta plaques which cause Alzheimer's Disease. We are encouraged by yet another study that suggests the versatile curcumin may lower heart failure risk," said Steven M. Schorr, Chairman and CEO of Bioponic. "More than 5 million Americans are living with heart failure, and 550,000 new cases are diagnosed each year, according to the American Heart Association. The potential that our Curecumin(TM) product (http://www.curecumin.com) could provide a viable treatment strategy for those at risk for heart failure is very exciting. If proven effective, we may have an efficacious, cost effective, natural treatment for heart failure sufferers."